Manuela Cappelletti | Immunology | Industry Impact Award

Published on by Molecular Biologist

Mrs. Manuela Cappelletti | Immunology | Industry Impact Award 

Senior lab biologist | TAKIS srl | Italy

Mrs. Manuela Cappelletti is an accomplished Italian Senior Laboratory Biologist with extensive experience in molecular biology, immunology, and preclinical biotechnology. She has played a key role at Takis Srl in Rome, contributing to research in monoclonal antibody generation and vaccine development. Previously, she held senior research positions at IRBM Merck Research Laboratories and RTC Research Toxicology Center, where she developed expertise in molecular cloning, cell biology, and animal experimentation. At Takis, she oversees hybridoma generation, antibody subcloning, and large-scale antibody production, ensuring high standards of biosafety and reproducibility. Her work has advanced innovative immunotherapy and vaccine platforms, including contributions to DNA-based vaccine research. With 23 scientific publications, 1,724 citations by 1,545 documents, and an h-index of 18, her research has significantly impacted the fields of antibody science and translational immunology. Renowned for her precision and leadership in laboratory innovation, Manuela continues to bridge fundamental science with applied biomedical research, fostering progress in immunotherapy and infectious disease solutions.

Profile: Scopus | ORCID

Featured Publications

Cappelletti, M., et al. (n.d.). Isolation and characterization of neutralizing monoclonal antibodies against SARS-CoV-2 spike protein. Antibodies (Basel). Cited by 12.

Cappelletti, M., et al. (n.d.). COVID-eVax: An electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD. Molecular Therapy, 30(4). Cited by 58.

Cappelletti, M., et al. (n.d.). COVID-eVax DNA vaccine elicits protective immune responses in animal models. bioRxiv. Cited by 72.

Cappelletti, M., et al. (n.d.). Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. Journal of Gene Medicine, 5(3). Cited by 130.

Cappelletti, M., et al. (n.d.). C/EBP beta and acute phase gene regulation in liver cells. Cell Death and Differentiation, 3(2). Cited by 45.

 

Alessia Muzi | Immunology | Women Researcher Award

Published on by Molecular Biologist

Dr. Alessia Muzi | Immunology | Women Researcher Award

Principal investigator | Takis srl | Italy

Dr. Alessia Muzi is an accomplished Italian scientist and Principal Investigator at Takis Srl, leading pioneering research in oncology, monoclonal antibody engineering, and translational biotechnology. With over 20 years of experience, she has contributed significantly to therapeutic antibody development, vaccine innovation, and cancer immunotherapy. She holds a Ph.D. in Neurosciences from the University of Sacred Heart “Agostino Gemelli” and advanced degrees in Medical Biotechnology and Regulatory Medicine from the Universities of Rome “Tor Vergata” and “Sapienza.” As Head of the Monoclonal Antibody Laboratory at Takis, Dr. Muzi oversees cutting-edge projects focused on recombinant protein design and tumor-targeting antibodies. Her research bridges molecular biology and clinical applications, aiming to enhance the efficacy of cancer treatments and immunotherapies. Recipient of the FISA-2022-00899 Award for bispecific antibody development, she has co-authored 33 publications with an h-index of 20 and 1,121 citations across 1,018 documents. Dr. Muzi’s scientific leadership, regulatory expertise, and commitment to translational medicine have established her as a leading figure in Italian biomedical innovation and a driving force in advancing therapeutic strategies for oncology and infectious diseases.

Profile: Scopus | ORCID

Featured Publications

Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity. (2025). Antibodies. Cited by 12.

Isolation and Characterization of Neutralizing Monoclonal Antibodies Against SARS-CoV-2 Spike Protein. (2024). Antibodies. Cited by 25.

A Linear DNA Vaccine Candidate Encoding SARS-CoV-2 RBD in Domestic Cats. (2023). Mol Ther Methods Clin Dev. Cited by 9.

A First-in-Human Trial of COVID-eVax DNA Vaccine. (2022). Mol Ther. Cited by 40.

Persistent B Cell Memory After SARS-CoV-2 Vaccination. (2022). Cell Host Microbe. Cited by 58.

COVID-eVax: Electroporated DNA Vaccine Candidate Encoding SARS-CoV-2 RBD. (2022). Mol Ther. Cited by 65.

The Nuts and Bolts of SARS-CoV-2 Spike RBD Heterologous Expression. (2021). Biomolecules. Cited by 33.